Status:

COMPLETED

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Lead Sponsor:

National Institute on Drug Abuse (NIDA)

Conditions:

Methamphetamine Dependence

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior ...

Detailed Description

The primary objective of this study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days ...

Eligibility Criteria

Inclusion

  • Must have a DSM-IV diagnosis of methamphetamine dependence as determined by MINI
  • Must have at least 1 amphetamine or methamphetamine positive urine specimen after the start of screening and before randomization or provide information to verify recent use if a positive urine sample can't be obtained
  • Must report using methamphetamine for 29 days or less during the 30 day period prior signing consent using the timeline follow-back method
  • Must be willing and able to comply with study procedures
  • Must be able to verbalize and understand consent forms and provide written informed consent
  • Must be seeking treatment for methamphetamine dependence

Exclusion

  • Please contact study site for more information

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2011

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT00687713

Start Date

May 1 2008

End Date

May 1 2011

Last Update

March 21 2017

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

UCLA Integrated Substance Abuse Program

Los Angeles, California, United States, 90025

2

South Bay Treatment Center

San Diego, California, United States, 92115

3

Addiction and Pharmacology Research Laboratory

San Francisco, California, United States, 94110

4

Friends Research Institute

Torrance, California, United States, 90502